The Lymphoma-Associated Macrophage to Hodgkin-Reed-Sternberg Cell Ratio Is a Poor Prognostic Factor in Classic Hodgkin Lymphoma Patients

Procházka, Vít; Papajík, Tomáš; Dyskova, Tereza; Dihel, Martin; Brychtová, Světlana; Prouzová, Zuzana; Kriegová, Eva; Lukásová, M; Hanáčková, Veronika

doi:10.1016/j.clml.2019.07.001

Cited by 2 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The expressions of both TAM markers, CD68, and CD163 [306] are essential predictors of complete remission in CHL patients [307]. A high ratio of LAMs to Hodgkin-Reed-Sternberg cells at diagnosis is associated with a higher risk of CHL progression or death [308].…”

Section: Hodgkin Lymphomamentioning

confidence: 99%

Macrophage-Based Therapeutic Strategies in Hematologic Malignancies

Khalili,

Zeinali,

Moghadam Fard

et al. 2023

Cancers

View full text Add to dashboard Cite

Macrophages are types of immune cells, with ambivalent functions in tumor growth, which depend on the specific environment in which they reside. Tumor-associated macrophages (TAMs) are a diverse population of immunosuppressive myeloid cells that play significant roles in several malignancies. TAM infiltration in malignancies has been linked to a poor prognosis and limited response to treatments, including those using checkpoint inhibitors. Understanding the precise mechanisms through which macrophages contribute to tumor growth is an active area of research as targeting these cells may offer potential therapeutic approaches for cancer treatment. Numerous investigations have focused on anti-TAM-based methods that try to eliminate, rewire, or target the functional mediators released by these cells. Considering the importance of these strategies in the reversion of tumor resistance to conventional therapies and immune modulatory vaccination could be an appealing approach for the immunosuppressive targeting of myeloid cells in the tumor microenvironment (TME). The combination of reprogramming and TAM depletion is a special feature of this approach compared to other clinical strategies. Thus, the present review aims to comprehensively overview the pleiotropic activities of TAMs and their involvement in various stages of cancer development as a potent drug target, with a focus on hematologic tumors.

show abstract

Section: Hodgkin Lymphomamentioning

confidence: 99%

Macrophage-Based Therapeutic Strategies in Hematologic Malignancies

Khalili,

Zeinali,

Moghadam Fard

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…В ранее проведенных исследованиях нами уста новлено прогностическое значение опухольассоци ированных макрофагов (CD163, CD68) при нодуляр ном склерозе кЛХ [11][12][13]. Повышение доли клеток, экспрессирующих CD163, коррелирует с вероятностью развития рецидивов заболевания и низкой общей вы живаемостью пациентов, что частично совпадает с ре зультатами зарубежных исследований, которые носят преимущественно описательный характер [9,[14][15][16]. Значимость CD68 как маркерапредиктора течения кЛХ в настоящее время доказана не в полной мере, хотя встречаются отдельные работы, в которых отра жена важная роль данного маркера [16,17].…”

Section: теоретические аспекты и фундаментальные исследования -в практику врача-онкологаunclassified

Prognostic significance of CD163- and CD68-expressing macrophages in nodular sclerosis Hodgkin lymphoma

et al. 2022

View full text Add to dashboard Cite

The objective of the study was to determine the clinical and morphological criteria and prognostic significance of CD163- and CD68-expressing macrophages in formalin-fixed paraffin-embedded (FFPE) lymph node samples of nodular sclerosis Hodgkin lymphoma.Materials and methods. We have studied clinical and laboratory characteristics and treatment results of 52 patients with newly diagnosed nodular sclerosis Hodgkin lymphoma. The treatment efficacy was assessed after 2–4 courses of chemotherapy by positron emission tomography combined with computed tomography scan (PET-CT) according to the Deauville scale.Results. In FFPE lymph node samples, differences in the localization and relative number of CD163-positive macrophages in patients of both study groups were determined. Morphometric counting of CD68-positive cells did not reveal statistically significant intergroup differences. The threshold of CD163-positive cells has been established. The relationship between the CD68 expression level and the response to frontline therapy was not revealed. The ratio of tumorassociated macrophages in each patient was assessed by the CD163/CD68 index. The threshold of the index was determined, which allows predicting the course of nodular sclerosis Hodgkin lymphoma.Conclusion. The following parameters could be used as additional morphological criteria for predicting the response to frontline therapy in patients with nodular sclerosis Hodgkin lymphoma: tissue distribution pattern and quantitative calculation of macrophage-histiocytic microenvironment subpopulation composition. The results could be used to risk group stratification of patients with nodular sclerosis Hodgkin lymphoma in order to predict the response to initial phase of therapy, as well as to determine personalized treatment approaches.

show abstract

The Lymphoma-Associated Macrophage to Hodgkin-Reed-Sternberg Cell Ratio Is a Poor Prognostic Factor in Classic Hodgkin Lymphoma Patients

Cited by 2 publications

References 23 publications

Macrophage-Based Therapeutic Strategies in Hematologic Malignancies

Macrophage-Based Therapeutic Strategies in Hematologic Malignancies

Prognostic significance of CD163- and CD68-expressing macrophages in nodular sclerosis Hodgkin lymphoma

Contact Info

Product

Resources

About